Hello
wanted to start a new thread on this … Both the Biocon divestiture to Eris and their acquisition of Swiss Parenterals.
Market seems to be overly concerned about rising debt levels in the company.
Market is also worried that all cash flows are being invested in acquisitions and feel some will go wrong.
In a way only time can say . But management seems to be quite convincing.
Malolan
| Subscribe To Our Free Newsletter |
